Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2016-01-20552,2016,Field 2016 Thorax,14000,"Once-only lung cancer screening using low-dose Computed Tomography CT VERSUS Standard/Usual Care IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- A 5-year lung cancer risk of =5%.",26645413,"Healthy; Age- 41 to 64 years, >=65 years; Gender- Both; Country- United Kingdom; Other- A 5-year lung cancer risk of =5%.",Once-only lung cancer screening using low-dose Computed Tomography CT,UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening.,Standard/Usual Care,NE
2014-01-16411,2014,Parmar 2014 J Gastrointest Surg,Dominated,Early elective cholecystectomy VERSUS observation IN Specific disease- mild biliary disease; Age- >=65 years; Gender- Not Specified; Country- United States.,24919433,Specific disease- mild biliary disease; Age- >=65 years; Gender- Not Specified; Country- United States.,Early elective cholecystectomy,Cost-effectiveness of elective laparoscopic cholecystectomy versus observation in older patients presenting with mild biliary disease.,observation,NW
2012-01-08531,2012,Manca 2012 Value Health,26000,First-line combination therapy of fluorouracil plus irinotecan VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer,22264968,UK patients diagnosed with colorectal cancer,First-line combination therapy of fluorouracil plus irinotecan,The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).,First-line fluorouracil until treatment failure followed by single agent irinotecan,NE
2012-01-08531,2012,Manca 2012 Value Health,26000,First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and irinotecan (IrMdG regimen) VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer,22264968,UK patients diagnosed with colorectal cancer,First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and irinotecan (IrMdG regimen),The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).,First-line fluorouracil until treatment failure followed by single agent irinotecan,NE
2012-01-08531,2012,Manca 2012 Value Health,50000,First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and oxaliplatin (OxMdG regimen) VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer,22264968,UK patients diagnosed with colorectal cancer,First-line modification of de Gramont regimen (MdG) regimen until treatment failure followed by doublet therapy with MdG and oxaliplatin (OxMdG regimen),The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).,First-line fluorouracil until treatment failure followed by single agent irinotecan,NE
2012-01-08531,2012,Manca 2012 Value Health,99000,First-line doublet therapy with modification of de Gramont regimen (MdG) and oxaliplatin (OxMdG) VERSUS First-line fluorouracil until treatment failure followed by single agent irinotecan IN UK patients diagnosed with colorectal cancer,22264968,UK patients diagnosed with colorectal cancer,First-line doublet therapy with modification of de Gramont regimen (MdG) and oxaliplatin (OxMdG),The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS).,First-line fluorouracil until treatment failure followed by single agent irinotecan,NE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
